Dr. Burton E. Sobel

• 
  www.sec.gov/Archives/edgar/data/1196855/0001123292-09-0 - [Cached Version]
  Published on: 3/3/2009    Last Visited: 3/4/2009  

  0001196855 SOBEL BURTON E 201 INDUSTRIAL ROAD, SUITE 310 SAN CARLOS CA 94070 1 0 0 0

• 
  www.ariad.com/wt/page/bod - [Cached Version]
  Published on: 3/4/2007    Last Visited: 3/4/2007  

  Burton E. Sobel, M.D. Director of Cardiovascular Research Institute, University of Vermont
  ...
  Burton E. Sobel, M.D.

• 
  www.sec.gov/Archives/edgar/data/884731/0001157523-07-00 - [Cached Version]
  Published on: 4/16/2007    Last Visited: 4/22/2007  

  0001196855 SOBEL BURTON E C/O ARIAD PHARMACEUTICALS, INC. 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 1 0 0 0

• 
  www.sec.gov/Archives/edgar/data/884731/0001157523-08-00 - [Cached Version]
  Published on: 1/22/2008    Last Visited: 1/23/2008  

  0001196855 SOBEL BURTON E C/O ARIAD PHARMACEUTICALS, INC 21 LANDSDOWNE STREET CAMBRIDGE MA 02139 1 0 0 0

• 
  www.fahc.org/Medicine/Cardiology/fellowship.html - [Cached Version]
  Published on: 3/5/2007    Last Visited: 3/5/2007  

  Burton E. Sobel, MDDirector of Cardiovascular Research Institute
  
  Group of Fellows
  ...
  Schneider, DJ, Baumann, PQ, Holmes, MB, Taatjes, DJ, Sobel, BE: Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin.
  ...
  Holmes, MB, Schneider, DJ, Hayes, M, Sobel, BE, Mann KG: A novel bedside, tissue factor-dependent clotting assay permitting improved assessment of both antithrombotic and antiplatelet therapy.
  ...
  Holmes, MB, Kabbani, SS, Terrien, CM, Watkins, MW, Sobel, BE, Schneider, DJ: Quantification by flow cytometry of the efficacy fo and inter-individual variation of platelet inhibition induced by treatment with tirofiban and abciximab.
  ...
  Kabbani, SS, Watkins, MW, Ashikaga, T, Terrien, EF, Holoch, PA, Sobel, BE, Schneider, DJ: Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention.
  ...
  Kabbani SS Watkins, MW, Terrien, EF, Holoch, PA, Sobel, BE, Schneider, DJ: Platelet reactivity in coronary ostial blood: a reflection of the thrombotic state accompanying plaque rupture and of the adequacy of anti-thrombotic therapy.
  ...
  Chen, Y, Sobel, BE, Schneider, DJ: Effect of fatty acid chain length and thioesterification on the augmentation of expression of plasminogen activator inhibitor-1.
  ...
  Aggarwal, A, Kabbani, SS, Rimmer, JM, Gennari, JF, Taatjes, DJ, Sobel, BE, Schneider, DJ: Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease, a potential contributor to cardiovascular risk.
  ...
  Aggarwal, A, Sobel, BE, Schneider, DJ: Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: Implications for coronary intervention.
  ...
  Aggarwal, A, Schneider, DJ, Terrien, EF, Terrien, CM, Sobel, BE, Dauerman, HL: Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interlukin-6, and interleukin- receptor antagonist after coronary arterial stenting.
  ...
  Aggarwal, A, Schneider, DJ, Sobel, BE, Dauerman, HL: Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting.
  ...
  Aggarwal, A, Schneider, DJ, Terrien, EF, Sobel, BE, Dauerman, HL: Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD 40 ligand indicative of inflammation associated with culprit coronary atherosclerotic plaques.
  ...
  Keating, FK, Sobel, BE, Schneider, DJ: Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus.
  ...
  Aggarwal, A, Whitaker, DA, Rimmer, JM, Solomon, RJ, Gennari, FJ, Sobel, BE, Schneider, DJ: Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing hemodialysis.
  ...
  Gutierrez, MJ, Aggarwal, A, Gilbert, K, Sobel, BE, Dauerman, HL: Use of femoral closure devices as part of a pharmacoinvasive reperfusion strategy.
  ...
  Aggarwal, A., Schneider, D.J., Sobel, B.E., Dauerman, H.L.: Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary stenting.
  ...
  Keating, F.K., Sobel, B.E., Schneider, D.J.: Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes.
  ...
  Chen, Y., Kelm, R.J., Budd, R.C., Sobel, B.E., Schneider, D.J.: Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1.
  ...
  Aggarwal A., Whitaker D.A., Rimmer, J.M., Solomon, R.J., Gennari, F.J., Sobel, B.E., Schneider, D.J.: Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing hemodialysis.
  ...
  Keating, F.K., Sobel, B.E., Whitaker D.A., Schneider, D.J.: Augmentation of Inhibitory Effects of Glycoprotein IIb-IIIa Antagonists in Patients with Diabetes.
  ...
  Schneider, D.J., Hayes, M., Taatjes, H., Wadsworth, M., Rincon, M., Taatjes, D.J., Sobel, B.E.: Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type-1 (PAI-1).
  ...
  Keating, F.K., Whitaker D.A., Kabbani, S.S., Ricci M.A., Sobel, B.E., Schneider, D.J.: Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis.

• 
  www.fletcher-allen.com/Medicine/Medicine_Hub/staff_dtl_ - [Cached Version]
  Published on: 9/14/2007    Last Visited: 9/14/2007  

  Burton E. Sobel, MD, FACC, FACP (Master), FAHA
  
  Departments & Services > University Cardiology Associates > Burton E. Sobel, MD, FACC, FACP (Master), FAHA
  ...
  Burton E. Sobel, MD, FACC, FACP (Master), FAHA
  ...
  Burton E. Sobel, MD, FACC, FACP (Master), FAHA
  ...
  Dr. Sobel is Director of the Cardiovascular Research Institute at the University of Vermont.Dr. Sobel has served on countless professional societies and editorial boards, and has been repeatedly honored by a variety of professional and business groups, including several awards from the American Heart Association.He was also given a Research Career Development Award from the NIH, Distinguished Scientist Award, from the American College of Cardiology, a Distinguished Achievement Award from the AHA and the ACC, an International Recognition Award from the Heart Research Foundation, and a Mastership from the American College of Physicians.Dr. Sobel has lectured and published widely, served as a consultant on many corporate boards, holds several patents, and has a particular research interest in the connection between diabetes and heart disease.He and his wife, Susan, a family therapist, live in Colchester and have two grown children.
  ...
  This work provided a foundation for subsequent large-scale, multicenter clinical trials in which Dr. Sobel played a leadership role that demonstrated the efficacy of coronary thrombolysis with clot-selective agents, heparin, and aspirin in the reduction of death associated with coronary artery disease and acute myocardial infarction;
  ...
  Co-Investigator: Dr. Burton E. Sobel; Dr. Kenneth G. Mann (PI)
  ...
  Co-Investigator: Dr. Burton E. Sobel; Dr. Martin M. LeWinter (PI)
  ...
  Principal Investigator: Dr. Burton E. Sobel
  ...
  Co-Investigator: Dr. Burton E. Sobel; Dr. Charles G. Irvin (PI)
  ...
  Co-Investigator: Dr. Burton E. Sobel; Dr. Martin M. LeWinter (PI)
  ...
  Principal Investigator: Dr. Burton E. Sobel
  ...
  Principal Investigator: Dr. Burton E. Sobel
  ...
  Principal Investigator: Dr. Burton E. Sobel
  ...
  Dong, J., Fujii, S., Imagawa, S., Matsumoto, S., Matsushita, M., Todo, S., Tsutsui, H., and Sobel, B. E.: Interleukin (IL)-1 and IL-6 induction of plasminogen activator inhibitor-1 in hepatocytes through a statin sensitive signaling pathway: Implications for clinical effects.Am.J.Physiol., in press.
  
  Sobel, B. E., Schneider, D. J., Lee, Y.-H., and Pratley, R. E.: Insulin resistance increases PAI-1 in the heart.Biochem.Biophys.Res.Commun.346:102-107, 2006.
  
  Sobel, B. E. for the BARI 2D Trial Investigators: Ancillary studies in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial: Synergies and opportunities.Am.J.Cardiol.97(Suppl.):53G-58G, 2006.

• 
  www.sec.gov/Archives/edgar/data/1196855/0001196855-05-0 - [Cached Version]
  Published on: 11/22/2005    Last Visited: 11/23/2005  

  0001196855 SOBEL BURTON E FLETCHER HOUSE/MCHV 111 COLCHESTER AVENUE BURLINGTON VT 05401 1 0 0 0

• 
  www.clda.com/aboutus/directors.cfm - [Cached Version]
  Published on: 2/15/2008    Last Visited: 2/15/2008  

  Burton E. Sobel, M.D.

• 
  www.sec.gov/Archives/edgar/data/716646/0000950135-08-00 - [Cached Version]
  Published on: 7/29/2008    Last Visited: 7/30/2008  

  The Nominating and Governance Committee recommended, and the Board of Directors nominated, Randal J. Kirk, Andrew J. Fromkin, Larry D. Horner, Arthur B. Malman, Burton E. Sobel, M.D. and Richard J. Wallace as nominees for election at the annual meeting.
  ...
  Burton E. Sobel, M.D.
  ...
  Burton E. Sobel, M.D. has been at the University of Vermont since 1994 where he is currently Professor of Medicine, Director of the Cardiovascular Research Institute, and Professor of Biochemistry.Dr. Sobel has been a trustee of Fletcher Allen Health Care Center in Burlington, Vermont.Previously, he held senior academic and administrative positions at Washington University School of Medicine and Barnes Hospital from 1973 to 1994, and at the University of California, San Diego, from 1968 to 1973.Dr. Sobel completed postgraduate training at the Peter Bent Brigham Hospital, Boston and the National Institutes of Health, Bethesda and received his M.D., magna cum laude, from Harvard University and his A.B. from Cornell University.Dr. Sobel is President of the Society for Experimental Biology and Medicine and also serves as a member of the Board of Directors of Nuvelo, Inc. and Ariad Pharmaceuticals, Inc., both publicly-traded life science companies.Dr. Sobel also served as a member of the Board of Directors of New River Pharmaceuticals Inc., a publicly-traded specialty pharmaceutical company focused on developing novel pharmaceuticals and improved versions of widely-prescribed drugs, from 2004 until its acquisition by Shire plc in April 2007.
  ...
  The members of the Audit Committee are Larry D. Horner (Chair), Arthur B. Malman, and Burton E. Sobel, M.D.
  ...
  The Nominating and Governance Committee consists of Burton E. Sobel, M.D. (Chair) and Arthur B. Malman, each of whom the Board has determined meets the independence requirements as defined by applicable Nasdaq Stock Market standards governing the independence of directors.
  ...
  Burton E. Sobel, M.D.

• 
  www.implu.com/person/58411 - [Cached Version]
  Last Visited: 3/4/2009  

  SOBEL BURTON E ARIAD PHARMACEUTICALS INC

Page:  1 2 3 4 5